Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|October 21, 2017
Are we prepared for emerging flaviviruses in Europe? Challenges for vaccinationPatricia Kaaijk, Willem LuytjesHuman Vaccines & Immunotherapeutics|September 5, 2015
Vaccination against Lyme disease: Are we ready for it?Patricia Kaaijk, Willem LuytjesHuman Vaccines & Immunotherapeutics|February 28, 2013
Vaccination against RSV: is maternal vaccination a good alternative to other approaches?Patricia Kaaijk, Willem Luytjes, Nynke Y RotsHuman Vaccines & Immunotherapeutics|October 22, 2013
Routine vaccination against MenB: considerations for implementationPatricia Kaaijk, Arie van der Ende, Willem LuytjesAntiviral Research|May 18, 2016
RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptorsLenny van Mechelen, Willem Luytjes, Cornelis A M de Haan, et al.Vaccine|June 21, 2011
An international technology platform for influenza vaccinesJan Hendriks, Marit Holleman, Otto de Boer, et al.Frontiers in Immunology|April 11, 2019
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and DiseaseElisabeth A van Erp, Willem Luytjes, Gerben Ferwerda, et al.Frontiers in Immunology|May 6, 2014
T cell responses to viral infections - opportunities for Peptide vaccinationSietske Rosendahl Huber, Josine van Beek, Jørgen de Jonge, et al.Virology Journal|June 8, 2010
A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton ratsMyra N Widjojoatmodjo, Jolande Boes, Marleen van Bers, et al.BMC Public Health|December 25, 2012
Contributing factors to influenza vaccine uptake in general hospitals: an explorative management questionnaire study from the NetherlandsJosien Riphagen-Dalhuisen, Joep C F Kuiphuis, Arjen R Procé, et al.Pageof 3